Page 90 - 《中国药房》2023年13期

[ 2 ] MEHTA Y，HEGDE A，PANDE R，et al. Methicillin- System Pharmacists，the Infectious Diseases Society of
resistant Staphylococcus aureus in intensive care unit set‐ America，and the Society of Infectious Diseases Pharma‐
ting of India：a review of clinical burden，patterns of cists[J]. Am J Health Syst Pharm，2009，66（1）：82-98.
prevalence，preventive measures，and future strategies[J]. [10] TSUTSUURA M，MORIYAMA H，KOJIMA N，et al. The
Indian J Crit Care Med，2020，24（1）：55-62. monitoring of vancomycin：a systematic review and meta-
[ 3 ] RYBAK M J，LE J，LODISE T P，et al. Therapeutic moni‐ analyses of area under the concentration-time curve-
toring of vancomycin for serious methicillin-resistant guided dosing and trough-guided dosing[J]. BMC Infect
Staphylococcus aureus infections：a revised consensus Dis，2021，21（1）：153.
guideline and review by the American Society of Health- [11] KULLAR R，LEONARD S N，DAVIS S L，et al. Valida‐
System Pharmacists，the Infectious Diseases Society of tion of the effectiveness of a vancomycin nomogram in
America，the Pediatric Infectious Diseases Society，and achieving target trough concentrations of 15-20 mg/L sug‐
the Society of Infectious Diseases Pharmacists[J]. Am J gested by the vancomycin consensus guidelines[J]. Phar‐
Health Syst Pharm，2020，77（11）：835-864. macotherapy，2011，31（5）：441-448.
[ 4 ] COIA J E，WILSON J A，BAK A，et al. Joint Healthcare [12] 彭怀东，冯霞，王若伦. 重症患者万古霉素谷浓度监测回
Infection Society （HIS） and Infection Prevention Society 顾性研究[J]. 今日药学，2018，28（11）：767-770，778.
（IPS） guidelines for the prevention and control of [13] KANE S P. Vancomycin Calculator[EB/OL].（2017-11-25）
meticillin-resistant Staphylococcus aureus （MRSA） in [2022-09-20]. https：//clincalc.com/Vancomycin/Retired.
healthcare facilities[J]. J Hosp Infect，2021，118S：S1-S39. aspx.
[ 5 ] BROWN N M，BROWN E M，GROUP G D. Treatment of [14] MATSUMOTO K，ODA K，SHOJI K，et al. Clinical prac‐
methicillin-resistant Staphylococcus aureus （MRSA）：up‐ tice guidelines for therapeutic drug monitoring of vanco‐
dated guidelines from the UK[J]. J Antimicrob Che‐ mycin in the framework of model-informed precision do-
mother，2021，76（6）：1377-1378. sing：a consensus review by the Japanese Society of
[ 6 ] HE N，SU S，YE Z K，et al. Evidence-based guideline for Chemotherapy and the Japanese Society of Therapeutic
therapeutic drug monitoring of vancomycin：2020 update Drug Monitoring[J]. Pharmaceutics，2022，14（3）：489.
by the division of therapeutic drug monitoring，Chinese [15] WINTER M E. Basic clinical pharmacokinetics[M]. 5th
Pharmacological Society[J]. Clin Infect Dis，2020，71 ed. Philadelphia：Lippincott Williams & Wilkins，2010：
（Suppl 4）：S363-S371. 459-487.
[ 7 ] REUTER S E，STOCKER S L，ALFFENAAR J W C，et [16] KHWAJA A. KDIGO clinical practice guidelines for acute
al. Optimal practice for vancomycin therapeutic drug kidney injury[J]. Nephron Clin Pract，2012，120（4）：c179-
monitoring：position statement from the Anti-infectives c184.
Committee of the International Association of Therapeutic [17] 黄英姿，邱海波. 药代动力学导向的重症感染患者抗生
Drug Monitoring and Clinical Toxicology[J]. Ther Drug 素个体化与精准化治疗[J]. 中华内科杂志，2016，55（6）：
Monit，2022，44（1）：121-132. 425-427.
[ 8 ] MATSUMOTO K，TAKESUE Y，OHMAGARI N，et al. [18] 明丹丹，李军，许璇，等. 真实世界研究的方法及其在临
Practice guidelines for therapeutic drug monitoring of van‐ 床研究中的应用[J]. 中国药房，2018，29（15）：2138-2143.
comycin：a consensus review of the Japanese Society of [19] STEINMETZ T，ELIAKIM-RAZ N，GOLDBERG E，et
Chemotherapy and the Japanese Society of Therapeutic al. Association of vancomycin serum concentrations with
Drug Monitoring[J]. J Infect Chemother，2013，19（3）： efficacy in patients with MRSA infections：a systematic re‐
365-380. view and meta-analysis[J]. Clin Microbiol Infect，2015，21
[ 9 ] RYBAK M，LOMAESTRO B，ROTSCHAFER J C，et al. （7）：665-673.
Therapeutic monitoring of vancomycin in adult patients：a （收稿日期：2022-11-07 修回日期：2023-06-16）
consensus review of the American Society of Health- （编辑：胡晓霖）

· 1616 · China Pharmacy 2023 Vol. 34 No. 13 中国药房 2023年第34卷第13期